The shortcoming of this study is that, although a preclinical model of co-culture was developed to validate the mechanism of action of SYNGR4, there are discrepancies between the co-culture model and the real, complex tumor immune microenvironment, which, on the other hand, differs to some extent from that in humans in mice, and thus further in vivo experiments are needed to assess the therapeutic potential of SYNGR4. The gene discussed is SYNGR4; the disease is neoplasm.